Baseline Understanding of Exposure Allows for Long-term Monitoring and
Development of Solutions
MILFORD, Mass., March 19 /PRNewswire-FirstCall/ -- Responding to recent reports regarding findings of trace levels of pharmaceuticals found in U.S. drinking water supplies, Waters Corporation (NYSE: WAT) announced today that it will offer qualified U.S. water authorities complimentary drinking water analysis for common over-the-counter and prescription antidepressant pharmaceutical compounds to help assess regional exposure and move towards forward-looking solutions.
"As a provider of analytical technologies capable of detecting trace levels of contaminants in water, food and the environment, Waters(R) is keenly aware of the broad impact that contaminants can have on our natural resources," said Rohit Khanna, Vice President of Worldwide Marketing for the Waters Division. "As scientists, we at Waters believe in the need - and have the solutions - to assess baseline data to measure contamination levels, if any. Through this program we hope to work in cooperation with U.S. water authorities to better assess the public's exposure to pharmaceutical residues and assist them with potential action plans."
For 50 years, Waters has been producing advanced environmental
solutions and working with regulatory and government agencies at all
levels. For example, the Associated Press reported that the U.S.
Environmental Protection Agency (EPA) recently published a method to test
for pharmaceutical and personal care products in water, soil, sediment, and
biosolids; a method which references Waters solutions throughout. More
recently, Waters is applying advance technology to deliver an automated
solution with improv
'/>"/>
| SOURCE Waters Corporation Copyright©2008 PR Newswire. All rights reserved |